Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alcon AG (ALC) vs Allstate Corp (ALL) Price & Performance

Allstate CorpTrade

Price performance (Past 24H)

Key statistics

Alcon AG vs Allstate Corp — how do they compare? Alcon AG trades at $75 (market cap $35.19B), while Allstate Corp trades at $262.54 (market cap $68.19B). The key difference: Allstate Corp is the larger of the two by market cap, and Allstate Corp pays the higher dividend (1.6%). Which is the better fit depends on your goals.

ALCALL
Market Cap
$35.19B$68.19B
Sector
HealthFinancials
52-Week High
$90.12$275.11
52-Week Low
$62.02$190.00
Enterprise Value
$39.03B$76.84B
Dividend Yield
0.49%1.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alcon AG

ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.

Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.

Allstate Corp

Allstate (ALL) trades at $267.00, down 2.95% on the day, but maintains a bullish technical signal with strong fundamental momentum. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, and has consistently exceeded expectations in recent quarters. Revenue growth is steady, with 2025 revenue at $67.07 billion and net income margin improving to 19.19%. The stock is attractively valued with a P/E of 5.35 and offers a dividend, with recent payouts of $1.08 per share.

The outlook for ALL is positive, driven by strong underwriting performance and earnings beats, though sustainability of peak profitability is a concern. Investment opportunity lies in its low valuation and dividend yield, but risks include potential normalization of underwriting results and competitive pressures. Analyst consensus is mixed with a $266.54 price target, indicating limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.

Read more on ALC

About Allstate Corp

On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.

Read more on ALL